IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M

IDEAYA Biosciences, Inc.

2026-Q1 EPS reported -$1.11 revenue$6,560,000

Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.
NDA submission for darovasertib under FDA RTOR planned H2 2026; complete data at ASCO 2026.
Cash equivalents and marketable securities $972.9M as of March 31, 2026; runway unchanged into 2030.
Net loss for Q1 2026 was $98.5M vs $83.3M in Q4 2025; R&D expenses $95.7M.
Appointed Dr. Theodora Ross as Chief Development Officer in February 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.